Based on these results, we suggest that drugs targeting PARP1, mitochondrial respiration, and ATP synthase may hold potential as chemotherapeutic agents when combined with DNA damage-inducing drugs in cardiovascular diseases, Alzheimer’s disease, and cancer. The gene discussed is PARP1; the disease is Alzheimer disease.